目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STUDY LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Objectives of secondary research
2.1.1.3 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key objectives of primary research
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS)
2.2.1.1 Company revenue estimation approach
2.2.1.2 Customer-based market estimation
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW
4.2 BREAST BIOPSY DEVICES MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
4.3 EUROPE: BREAST BIOPSY DEVICES MARKET, BY REGION AND APPLICATION, 2024
4.4 GEOGRAPHIC SNAPSHOT OF BREAST BIOPSY DEVICES MARKET

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing incidence of breast cancer
5.2.1.2 Expansion of private diagnostic chains and imaging centers
5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures
5.2.1.4 Growing awareness regarding early detection of breast cancer
5.2.1.5 Improved reimbursement scenario
5.2.2 RESTRAINTS
5.2.2.1 High cost of liquid biopsy tests
5.2.2.2 Stringent regulatory approval procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements
5.2.3.2 Growing collaboration and financial support from public and private sectors
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.3.2 REGULATORY LANDSCAPE
5.3.2.1 North America
5.3.2.1.1 US
5.3.2.1.2 Canada
5.3.2.2 Europe
5.3.2.3 Asia Pacific
5.3.2.3.1 Japan
5.3.2.3.2 China
5.3.2.3.3 India
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Ultrasound
5.7.1.2 Mammography-guided stereotactic biopsy
5.7.1.3 MRI
5.7.1.4 Contrast-enhanced mammography (CEM) guidance
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Gamma-guided biopsy systems
5.7.2.2 Molecular breast imaging (MBI)-guided biopsy
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 Surgical oncology technologies
5.7.3.2 Cryoablation and other minimally invasive ablation technologies
5.8 TRADE ANALYSIS
5.8.1 IMPORT DATA
5.8.2 EXPORT DATA
5.9 PATENT ANALYSIS
5.10 PORTER'S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 INTENSITY OF COMPETITIVE RIVALRY
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION
5.11.2 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY APPLICATION
5.12 CASE STUDY ANALYSIS
5.12.1 CASE STUDY 1: PET-GUIDED BREAST BIOPSY
5.12.2 CASE STUDY 2: EARLY-STAGE BREAST CANCER AMID COVID PANDEMIC
5.12.3 CASE STUDY 3: SAMPLING MULTIPLE SMALL LESIONS IN DENSE BREAST TISSUE
5.13 KEY CONFERENCES & EVENTS, 2025-2026
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS
5.14.2 BUYING CRITERIA
5.15 IMPACT OF 2025 US TARIFF ON BREAST BIOPSY DEVICES MARKET
5.15.1 INTRODUCTION
5.15.2 KEY TARIFF RATES
5.15.3 PRICE IMPACT ANALYSIS
5.15.4 IMPACT ON COUNTRY/REGION
5.15.4.1 US
5.15.4.2 Europe
5.15.4.3 Asia Pacific
5.15.5 IMPACT ON END-USE INDUSTRIES
5.16 IMPACT OF GENERATIVE AI/AI ON BREAST BIOPSY DEVICES MARKET
5.17 INVESTMENT & FUNDING SCENARIO

6 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE
6.1 INTRODUCTION
6.2 NEEDLE BREAST BIOPSY
6.2.1 CORE NEEDLE BIOPSY
6.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth
6.2.2 VACUUM-ASSISTED BIOPSY (VAB)
6.2.2.1 High diagnostic specificity and accuracy of technique to boost demand
6.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB)
6.2.3.1 Drawbacks associated with procedure to limit market growth
6.3 OPEN SURGICAL BREAST BIOPSY
6.3.1 EXCISIONAL BIOPSY
6.3.1.1 Risk of post-operative complications to hinder market growth
6.3.2 INCISIONAL BIOPSY
6.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth
6.4 LIQUID BREAST BIOPSY
6.4.1 CIRCULATING TUMOR CELLS
6.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market
6.4.2 CIRCULATING TUMOR DNA (CTDNA)
6.4.2.1 Low concentrations of ctDNA to make screening for clinically relevant mutations challenging
6.4.3 OTHER BIOMARKERS

7 BREAST BIOPSY DEVICES MARKET, BY PRODUCT
7.1 INTRODUCTION
7.2 BIOPSY NEEDLES
7.2.1 CORE NEEDLES
7.2.1.1 Early detection through core needle biopsy to boost growth
7.2.2 FINE ASPIRATION NEEDLES
7.2.2.1 Accurate clinical decisions for early cancer diagnosis to drive demand for fine aspiration needles
7.2.3 VACUUM-ASSISTED BIOPSY NEEDLES
7.2.3.1 Enhanced accuracy with vacuum-assisted tissue sampling to drive adoption
7.3 BIOPSY EQUIPMENT
7.3.1 CORE BIOPSY EQUIPMENT
7.3.1.1 Ability to streamline breast diagnosis with core biopsy technology to boost demand
7.3.2 VACUUM-ASSISTED BIOPSY EQUIPMENT
7.3.2.1 Advantages of VAB in breast biopsy to drive market growth
7.4 GUIDANCE SYSTEMS
7.4.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY
7.4.1.1 Advantages of technique to boost adoption in coming years
7.4.2 ULTRASOUND-GUIDED BIOPSY
7.4.2.1 Ability to create fine-grained pictures of breasts to drive growth
7.4.3 MRI-GUIDED BIOPSY
7.4.3.1 High cost and low specificity to affect demand
7.5 BIOPSY TABLES
7.5.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH
7.6 ASSAY KITS
7.6.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH
7.7 LIQUID BIOPSY INSTRUMENTS
7.7.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET
7.8 LOCALIZATION WIRES
7.8.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET
7.9 OTHER PRODUCTS

8 BREAST BIOPSY MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 EARLY CANCER SCREENING
8.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE SEGMENT GROWTH
8.3 THERAPY SELECTION
8.3.1 ABILITY OF PERSONALIZED THERAPY SELECTION TO ENHANCE TREATMENT EFFICACY TO DRIVE DEMAND
8.4 TREATMENT MONITORING
8.4.1 GROWING POPULARITY OF REAL-TIME TREATMENT MONITORING TO BOOST MARKET
8.5 RECURRENCE MONITORING
8.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS IN MARKET

9 BREAST BIOPSY DEVICES MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET
9.3 IMAGING CLINICS & DIAGNOSTIC CENTERS
9.3.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH
9.4 BREAST CARE CENTERS
9.4.1 INCREASING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO BOOST MARKET

10 BREAST BIOPSY DEVICES MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North America breast biopsy devices market during forecast period
10.2.3 CANADA
10.2.3.1 Surge in incidence of breast cancer and favorable government guidelines to support market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products in Germany
10.3.3 UK
10.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer to drive growth
10.3.4 FRANCE
10.3.4.1 Rising geriatric population to support market growth
10.3.5 ITALY
10.3.5.1 Evolving regulatory scenario for breast biopsy to boost market
10.3.6 SPAIN
10.3.6.1 Increased funding scenario to propel market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
10.4.3 JAPAN
10.4.3.1 Presence of universal healthcare reimbursement scenario and rising breast cancer cases
10.4.4 INDIA
10.4.4.1 Government initiatives to improve female health to drive market growth in India
10.4.5 AUSTRALIA
10.4.5.1 Rising research investments and awareness campaigns to support market growth
10.4.6 SOUTH KOREA
10.4.6.1 Rising R&D and promising clinical trials in country to positively impact market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Key market in Latin America owing to modernization of healthcare facilities
10.5.3 MEXICO
10.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN MEA REGION
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.3 GCC COUNTRIES
10.6.3.1 Growing healthcare infrastructure to fuel market growth
10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2024)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Procedure footprint
11.5.5.5 Application footprint
11.5.5.6 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of startup/SME players, by region
11.6.5.3 Competitive benchmarking of startup/SME players, product
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 THIS SEGMENT INCLUDES THE GROWTH STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE BREAST BIOPSY DEVICES MARKET BETWEEN JANUARY 2020 AND MAY 2025.
11.9.2 PRODUCT LAUNCHES & APPROVALS
11.9.3 DEALS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 HOLOGIC, INC.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.2.1 Deals
12.1.1.3 MnM view
12.1.1.3.1 Key strengths
12.1.1.3.2 Strategic choices
12.1.1.3.3 Weaknesses & competitive threats
12.1.2 DANAHER CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches & approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 BECTON, DICKINSON AND COMPANY
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 MnM View
12.1.3.3.1 Key strengths
12.1.3.3.2 Strategic choices
12.1.3.3.3 Weaknesses & competitive threats
12.1.4 ARGON MEDICAL
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches & approvals
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 QIAGEN
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 MERIT MEDICAL SYSTEMS
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches & approvals
12.1.6.3.2 Deals
12.1.7 MENARINI SILICON BIOSYSTEMS SPA
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches & approvals
12.1.7.3.2 Deals
12.1.8 GUARDANT HEALTH, INC.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches & approvals
12.1.8.3.2 Deals
12.1.8.3.3 Other developments
12.1.9 NEOGENOMICS LABORATORIES, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches & approvals
12.1.9.3.2 Deals
12.1.10 STERYLAB S.R.L
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 BIOCEPT, INC.
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 BIO-RAD LABORATORIES, INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches & approvals
12.1.13 F. HOFFMANN-LA ROCHE LTD.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 EXACT SCIENCES CORPORATION
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.14.3.1 Deals
12.1.15 SYSMEX INOSTICS (A SUBSIDIARY OF SYSMEX CORPORATION)
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Deals
12.1.16 THERMO FISHER SCIENTIFIC
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.16.3 Recent developments
12.1.16.3.1 Deals
12.1.17 FUJIFILM HOLDINGS CORPORATION
12.1.17.1 Business overview
12.1.17.2 Products offered
12.2 OTHER PLAYERS
12.2.1 CARDIFF ONCOLOGY INC.
12.2.2 MYRIAD GENETICS, INC.
12.2.3 ILLUMINA, INC.
12.2.4 FLUXION BIOSCIENCES, INC.
12.2.5 INRAD, INC.
12.2.6 IZI MEDICAL PRODUCTS
12.2.7 REMINGTON MEDICAL INC.
12.2.8 CP MEDICAL

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS